Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer

被引:136
|
作者
Joly, F.
Alibhai, S. M. H.
Galica, J.
Park, A.
Yi, Q. -L.
Wagner, L.
Tannock, I. F.
机构
[1] Ctr Francois Baclesse, Dept Med Oncol, F-14076 Caen, France
[2] Univ Toronto, Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[3] Northwestern Univ, Sch Med, Evanston, IL 60208 USA
关键词
neoplasm metastasis; prostatic neoplasms; quality of life; cognition; SUPPRESSION; FATIGUE;
D O I
10.1016/j.juro.2006.07.151
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Many patients with prostate cancer receive androgen deprivation therapy for long periods. We compared physical and cognitive function, and quality of life in a cross-sectional study of 57 patients receiving androgen deprivation therapy for nonmetastatic prostate cancer and 51 healthy age matched controls. Materials and Methods: Physical and daily function were measured by the 6-minute walk test, grip strength, the timed up and go test, and activities of daily living measures. Cognitive function was evaluated by the High Sensitivity Cognitive Screen and by a self-report prototype Functional Assessment of Cancer Therapy cognitive function subscale. Quality of life was assessed by the Functional Assessment of Cancer Therapy-General with the subscale for fatigue and by the Patient-Oriented Prostate Utility Scale. Results: Androgen deprivation therapy was given for a median of 1.8 years (range 0.4 to 7.4). Patients had lower median hemoglobin than controls (134 vs 148 gm/l, p < 0.0001). Performance on physical tests was similar in the 2 groups. Moderate or severe cognitive impairment by the High Sensitivity Cognitive Screen was similar for patients (23%) and controls (35%, p = 0.2). Self-reported cognitive dysfunction was also similar. Scores for the Functional Assessment of Cancer TherapyGeneral were similar but the Patient Oriented Prostate Utility Scale summary score was worse for patients (median 71 vs 86, p < 0.001). More patients reported severe fatigue (Functional Assessment of Cancer Therapy-Fatigue score less than 35, p = 0.03). Low energy, poor bladder control and loss of sexual function were reported in 36%, 47% and 95% of patients, and in 16%, 34% and 33% of controls, respectively. Conclusions: Patients treated with androgen deprivation therapy experience more symptoms and have worse fatigue than controls, but this study did not detect any effect on physical or cognitive function.
引用
收藏
页码:2443 / 2447
页数:5
相关论文
共 50 条
  • [1] Impact of Androgen-Deprivation Therapy on Physical Function and Quality of Life in Men With Nonmetastatic Prostate Cancer
    Alibhai, Shabbir M. H.
    Breunis, Henriette
    Timilshina, Narhari
    Johnston, Calvin
    Tomlinson, George
    Tannock, Ian
    Krahn, Murray
    Fleshner, Neil E.
    Warde, Padraig
    Canning, Sarah Duff
    Klotz, Lawrence
    Naglie, Gary
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (34) : 5038 - 5045
  • [2] Impact of Androgen-Deprivation Therapy on Cognitive Function in Men With Nonmetastatic Prostate Cancer
    Alibhai, Shabbir M. H.
    Breunis, Henriette
    Timilshina, Narhari
    Marzouk, Shireen
    Stewart, Diane
    Tannock, Ian
    Naglie, Gary
    Tomlinson, George
    Fleshner, Neil
    Krahn, Murray
    Warde, Padraig
    Canning, Sarah Duff
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (34) : 5030 - 5037
  • [3] Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy
    Herr, HW
    O'Sullivan, M
    JOURNAL OF UROLOGY, 2000, 163 (06) : 1743 - 1746
  • [4] Impact of androgen deprivation therapy on depressive symptoms in men with nonmetastatic prostate cancer
    Timilshina, Narhari
    Breunis, Henriette
    Alibhai, Shabbir
    CANCER, 2012, 118 (07) : 1940 - 1945
  • [5] Prevalence of Patients With Nonmetastatic Prostate Cancer on Androgen Deprivation Therapy in the United States
    Cetin, Karynsa
    Li, Shuling
    Blaes, Anne H.
    Stryker, Scott
    Liede, Alexander
    Arneson, Thomas J.
    UROLOGY, 2013, 81 (06) : 1184 - 1189
  • [6] Androgen Deprivation Therapy and Cognitive Function in Prostate Cancer
    Kluger, Jonathan
    Roy, Alicia
    Chao, Herta H.
    CURRENT ONCOLOGY REPORTS, 2020, 22 (03)
  • [7] Impact of Androgen Deprivation Therapy on Self-Reported Cognitive Function in Men with Prostate Cancer
    Marzouk, Shireen
    Naglie, Gary
    Tomlinson, George
    Canning, Sarah Duff
    Breunis, Henriette
    Timilshina, Narhari
    Alibhai, Shabbir M. H.
    JOURNAL OF UROLOGY, 2018, 200 (02) : 327 - 334
  • [8] Impact of Androgen Deprivation Therapy on Weight Gain Differs by Age in Men with Nonmetastatic Prostate Cancer
    Timilshina, Narhari
    Breunis, Henriette
    Alibhai, Shabbir M. H.
    JOURNAL OF UROLOGY, 2012, 188 (06) : 2183 - 2188
  • [9] The impact of long-term androgen deprivation therapy on cognitive function and socioeconomic decision making in prostate cancer patients
    Holtfrerich, Sarah Katharina Charlotte
    Knipper, Sophie
    Purwins, Janna
    Castens, Jasmin
    Beyer, Burkhard
    Schlomm, Thorsten
    Diekhof, Esther Kristina
    PSYCHO-ONCOLOGY, 2020, 29 (08) : 1338 - 1346
  • [10] Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood
    Reiss, Allison B.
    Gulkarov, Shelly
    Pinkhasov, Aaron
    Sheehan, Katie M.
    Srivastava, Ankita
    De Leon, Joshua
    Katz, Aaron E.
    MEDICINA-LITHUANIA, 2024, 60 (01):